HeartSciences (HSCS) Net Income towards Common Stockholders (2021 - 2026)

HeartSciences has reported Net Income towards Common Stockholders for 6 years, with the latest figure at -$2.0 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 21.97% year-over-year to -$2.0 million; the trailing twelve-month figure through Jan 2026 stood at -$8.5 million (up 1.73% YoY), and the FY2025 full-year result was -$8.9 million, down 32.93% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$2.0 million, up from -$2.4 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$1.2 million in Q1 2022, with the low at -$2.6 million in Q1 2025.
• Historically, Net Income towards Common Stockholders has averaged -$1.9 million across 5 years, with a median of -$1.9 million in 2024.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders plunged 109.25% — and 2026, when it advanced 21.97%.
• HeartSciences' Net Income towards Common Stockholders stood at -$1.8 million in 2022, then increased by 3.28% to -$1.7 million in 2023, then retreated by 20.26% to -$2.1 million in 2024, then fell by 11.9% to -$2.4 million in 2025, then rose by 15.41% to -$2.0 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$2.0 million (Q1 2026), -$2.4 million (Q4 2025), and -$2.1 million (Q3 2025), per Business Quant data.